通过促进树突细胞成熟,GPR41 缺乏在接受过 estreptozotocin 治疗的小鼠中加剧了1型糖尿病
Jia-Hong Li1,2, Ming Zhang3,4, Zhao-di Zhang3,4
1Department of Pediatric Laboratory, Affiliated Children's Hospital of Jiangnan University (Wuxi Children's Hospital), Jiangnan University, Wuxi, 214023, China.
Acta pharmacologica Sinica
|March 22, 2024
概括
G蛋白结合受体41 (GPR41) 缺陷通过破坏肠道免疫力和促进免疫细胞激活来加剧1型糖尿病 (T1D). 恢复GPR41可能为T1D提供新的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 微生物组研究 微生物组研究
背景情况:
- 肠道免疫平衡的破坏与1型糖尿病 (T1D) 易感性有关.
- G蛋白结合受体41 (GPR41),一个短链脂肪酸受体,对于肠道平衡至关重要.
研究的目的:
- 研究GPR41在1型糖尿病 (T1D) 进展中的作用.
- 探索GPR41对T1D免疫调节的影响.
主要方法:
- 在患有T1D的非肥胖糖尿病小鼠 (NOD) 中研究了GPR41表达.
- 使用GPR41缺陷 (Gpr41-/-) 和野生型小鼠在链毒素 (STZ) 诱导的T1D模型中.
- 分析免疫细胞功能,包括树突细胞 (DC) 成熟和T细胞迁移.
- 进行了骨髓衍生的树突细胞 (BMDC) 的采用转移.
主要成果:
- 在胰腺和结肠中减少GPR41表达与NOD小鼠T1D发展相关.
- Gpr41-/-小鼠显示STZ诱导的T1D恶化,肠道免疫失调增加,IFN-γ+ T细胞向胰腺的迁移增加.
- 缺乏GPR41抑制了SOCS表达和增加了DC中的STAT3酸化,促进了DC的成熟.
- 在NOD小鼠中,采用Gpr41-/- BMDCs的转移加速了T1D.
结论:
- 在T1D中,GPR41对于维持肠道和胰腺免疫平衡至关重要.
- 在T1D的背景下,GPR41作为树突细胞成熟的负调节剂.
- 对于1型糖尿病来说,GPR41是一个潜在的治疗点.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Pathophysiology of Diabetes
926
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
926
Dipeptidyl Peptidase 4 Inhibitors
184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
Oral Hypoglycemic Agents: Biguanides and Glitazones
196
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
196


